{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166104954",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104954",
  "name" : "Dutch Pharmacogenetics Working Group Guideline for imipramine and CYP2C19",
  "relatedDrugs" : [ {
    "objCls" : "Drug",
    "@id" : "https://www.pharmgkb.org/data/drug/PA449969",
    "@context" : "https://www.pharmgkb.org/jsonld/drug.jsonld",
    "id" : "PA449969",
    "name" : "imipramine"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA124",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA124",
    "symbol" : "CYP2C19",
    "name" : "cytochrome P450, family 2, subfamily C, polypeptide 19"
  } ],
  "source" : "DPWG",
  "summaryHtml" : "<p>The Dutch Pharmacogenetics Working Group Guideline for imipramine recommends to reduce the dose by 30% in CYP2C19 poor metabolizers, and monitor the plasma concentration of imipramine and desipramine or select alternative drug. For CYP2C19 intermediate metabolizers, select an alternative drug.</p>",
  "textHtml" : "<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for imipramine based on <em>CYP2C19</em> genotype [Article:<a href=\"/pmid/21412232\">21412232</a>]. </p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Phenotype (Genotype) </th><th> Therapeutic Dose Recommendation </th><th> Level of Evidence </th><th> Clinical Relevance </th></tr><tr><td> <em>CYP2C19</em> PM (*2/*2, *2/*3, *3/*3) </td><td> Reduce dose by 30% and monitor plasma concentration of imipramine and desipramine or select alternative drug (e.g. fluvoxamine, mirtazapine) </td><td> Published controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints </td><td> Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); international normalized ratio increase &lt; 4.5 <br/>Kinetic effect (statistically significant difference)  </td></tr><tr><td> <em>CYP2C19</em> IM (*1/*2, *1/*3, *17/*2, *17/*3) </td><td> Insufficient data to allow calculation of dose adjustment. Select alternative drug (e.g. fluvoxamine, mirtazapine) </td><td> Published controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints </td><td> Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); international normalized ratio increase &lt; 4.5 <br/>Kinetic effect (statistically significant difference)  </td></tr><tr><td> <em>CYP2C19</em> UM (*17/*17) </td><td>  None </td><td> no data was retrieved with the literature search </td><td> no data was retrieved with the literature search </td></tr></table><ul><li>#See <a href=\"http://www.pharmgkb.org/home/dutch_pharmacogenetics_working_group.jsp\">Methods</a> or <a href=\"http://www.pharmgkb.org/pmid/18253145\">PMID: 18253145</a> for definition of \"moderate\" quality.</li><li>Please see attached PDF for detailed information about the evaluated studies: <a href=\"/download.do?objCls=Attachment&amp;objId=imipramine_CYP2C19_271111.pdf\" title=\"link tip\">Imipramine CYP2C19</a></li></ul>"
}